Corvus Pharmaceuticals, Inc. (CRVS) is a publicly traded Healthcare sector company. As of October 3, 2026, CRVS trades at $10.91 with a market cap of $919.44M and a P/E ratio of -56.40. CRVS moved -0.18% today. Year to date, CRVS is +48.91%; over the trailing twelve months it is +54.83%. Its 52-week range spans $2.54 to $26.95. Analyst consensus is strong buy with an average price target of $29.50. Rallies surfaces CRVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks CRVS insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $10.91 |
| Market Cap | $919.44M |
| P/E Ratio | -56.40 |
| EPS | $-0.19 |
| Dividend Yield | 0.00% |
| 52-Week High | $26.95 |
| 52-Week Low | $2.54 |
| Volume | 1.13M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-15.28M |
| Gross Margin | 0.00% |
4 analysts cover CRVS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $29.50.